AI Article Synopsis
- Specialized ultrasound imaging modes can monitor and guide noninvasive and minimally-invasive thermal therapies.
- One method utilizes two-dimensional imaging to track temperature changes during treatments like HIFU and RF ablation, validated through various tests.
- The development of advanced imaging techniques enables real-time monitoring, enhancing the precision and effectiveness of thermal therapies with high spatial and temporal resolutions.
Article Abstract
We present specialized ultrasound imaging modes for monitoring and guidance of noninvasive and minimally-invasive thermal therapy. One mode is based on two-dimensional imaging of temperature change using diagnostic ultrasound. We have validated this method both in vivo and in vitro in monitoring the heating patterns produced by noninvasive HIFU source and minimally-invasive RF ablation device, respectively. In addition, a nonlinear method for imaging the quadratic echo components from HIFU-induced lesions has also been developed and tested in vivo. Illustrative results from both modes of imaging are presented. These results demonstrate the unique advantages of ultrasound as an image-guidance modality. Specifically, the high spatial and temporal resolutions that allow for imaging highly-localized short-duration therapeutic and sub-therapeutic HIFU beams. With the advent of highperformance computing hardware, these imaging modes are now implementable in real-time. This will lead to active realtime monitoring and control of a range of thermal therapies in the very near future.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1109/IEMBS.2009.5332711 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The promises and perils of circulating tumor DNA for monitoring immunotherapy response in non-small cell lung cancer.
Explor Target Antitumor Ther
November 2024
Division of Pulmonary, Critical Care, and Sleep Disorders Medicine, Department of Medicine, University of Louisville School of Medicine, Louisville, KY 40202, USA.
There has been a rapid expansion of immunotherapy options for non-small cell lung cancer (NSCLC) over the past two decades, particularly with the advent of immune checkpoint inhibitors. Despite the emerging role of immunotherapy in adjuvant and neoadjuvant settings though, relatively few patients will respond to immunotherapy which can be problematic due to expense and toxicity; thus, the development of biomarkers capable of predicting immunotherapeutic response is imperative. Due to the promise of a noninvasive, personalized approach capable of providing comprehensive, real-time monitoring of tumor heterogeneity and evolution, there has been wide interest in the concept of using circulating tumor DNA (ctDNA) to predict treatment response.
View Article and Find Full Text PDFThe rapid growth, invasiveness, and resistance to treatment of glioblastoma multiforme (GBM) underscore the urgent need for improved diagnostics and therapies. Current surgical practice is limited by challenges with intraoperative imaging, while recurrence monitoring requires expensive magnetic resonance or nuclear imaging scans. Here we introduce 'acoustic tumor paint', an approach to labeling brain tumors for ultrasound imaging, a widely accessible imaging modality.
View Article and Find Full Text PDFIdentifying and Understanding Seizure Liability in Drug Development.
Int J Toxicol
January 2025
Allucent, Cary, NC, USA.
Seizures are complex electrophysiological disturbances affecting one or more populations of brain neurons. Seizures following test article (TA) exposure pose significant challenges in drug development. This paper considers the diverse neurological manifestations, mechanisms, and functional and structural assessments needed to investigate TA-related seizure liabilities, with a particular focus on nonclinical species.
View Article and Find Full Text PDFTreatment outcomes with oral anti-hyperglycaemic therapies in people with diabetes secondary to a pancreatic condition (type 3c diabetes): A population-based cohort study.
Diabetes Obes Metab
January 2025
Department of Clinical and Biomedical Sciences, University of Exeter Medical School, Exeter, UK.
Aims: To assess outcomes of oral anti-hyperglycaemic therapies in people with diabetes secondary to a pancreatic condition (type 3c), where specific treatment guidance is limited.
Materials And Methods: Using hospital-linked UK primary care records (Clinical Practice Research Datalink; 2004-2020), we identified 7084 people with a pancreatic condition (acute pancreatitis, chronic pancreatitis, pancreatic cancer and haemochromatosis) preceding diabetes diagnosis (type 3c cohort), initiating oral glucose-lowering therapy (metformin, sulphonylureas, SGLT2-inhibitors, DPP4-inhibitors or thiazolidinediones), and without concurrent insulin treatment. We stratified by pancreatic exocrine insufficiency [PEI] (n = 5917 without PEI, 1167 with PEI) and matched to 97 227 type 2 diabetes (T2D) controls.
Apnea After 2-Month Vaccinations in Hospitalized Preterm Infants: A Randomized Clinical Trial.
JAMA Pediatr
January 2025
Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina.
Importance: Preterm infants are recommended to receive most vaccinations at the same postnatal age as term infants. Studies have inconsistently observed an increased risk for postvaccination apnea in preterm infants.
Objective: To compare the proportions of hospitalized preterm infants with apnea and other adverse events in the 48 hours after 2-month vaccinations vs after no vaccinations.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!